EUVIMEDEUVIMED entdecken
Open Access

Clinical and Genetic Predictors of Non‐Alcoholic Steatotic Liver Disease and Fibrosis in Lean Individuals

Karina Sato-Espinoza iD, Robert A Vierkant iD, Perapa Chotiprasidhi iD, Filippo Pinto E Vairo iD, Shulan Tian iD, Jun Ma iD, Daniel O'Brien iD, Konstantinos N Lazaridis iD, Carola Dlugosch iD, Carolin Scheider iD, Alina M Allen iD, Kirk J Wangensteen iD

Liver International · 2025

DOI: 10.1111/liv.70300 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2025. Verfasst von Karina Sato-Espinoza und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Liver Cirrhosis, Thinness. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS, national institutes of health national cancer institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims Steatotic liver disease (SLD) is characterised by liver fat accumulation exceeding 5%. Lean body weight (BMI ≤ 25 kg/m 2 ) with non‐alcoholic SLD is a rare phenotype, and the balance of risks related to metabolic conditions or genetic predisposition, or the risk of progressive liver disease, is not known. This study evaluates clinical and genetic predictors of non‐alcoholic SLD and advanced liver disease in lean individuals.

Methods

We used International Classification of Disease codes, radiology and pathology review to identify 177 lean non‐alcoholic SLD cases (47 cryptogenic, 130 MASLD), 677 matched lean controls, and 3090 overweight/obese SLD cases in the Mayo Clinic Biobank and Tapestry databases. We performed case–control and cross‐sectional comparisons of clinical and genetic factors between these groups, using univariable and multivariable analyses.

Results

Lean individuals with non‐alcoholic SLD exhibited metabolic and genetic profiles that were intermediate between those of lean controls without SLD and overweight/obese SLD individuals, including intermediate rates of diabetes, hypertension, hyperlipidaemia and of homozygosity for the risk allele of PNPLA3 . Multivariable analysis indicated that diabetes was an independent predictor of SLD among lean individuals. Among lean individuals with non‐alcoholic SLD, those with metabolic‐associated SLD (MASLD), as compared to those with cryptogenic SLD (without metabolic risk factor), were more likely to be homozygous for risk alleles in GCKR . The Fib‐4 score, a tool for screening advanced liver disease in SLD, accurately predicted advanced fibrosis among lean individuals with non‐alcoholic SLD.

Conclusion

Diabetes serves as a primary predictor of non‐alcoholic SLD in lean individuals. These results support the recommendation to screen for SLD in patients with diabetes, regardless of BMI. The GCKR risk allele is associated with MASLD in lean individuals, and the risk factors for cryptogenic SLD remain unclear.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseLiver CirrhosisThinnessHumansMaleFemaleMiddle AgedCase-Control StudiesCross-Sectional StudiesAdultRisk FactorsGenetic Predisposition to DiseaseBody Mass IndexObesityAdaptor Proteins, Signal TransducingMembrane ProteinsAgedLipaseAcyltransferasesPhospholipases A2, Calcium-Independent

Stichwörter der Autor:innen

Fib‐4 scoreMASLDdiabetesgermline variantssteatosis

Substanzen

PNPLA3 protein, humanAdaptor Proteins, Signal TransducingGCKR protein, humanMembrane ProteinsLipaseAcyltransferasesPhospholipases A2, Calcium-Independent

Autor:innen und Institutionen

  • Department of Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Quantitative Health Sciences, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Clinical Genomics, Mayo Clinic, Rochester, Minnesota, USA.
  • Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Quantitative Health Sciences, Division of Computational Biology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Medicine III, RWTH Aachen University, Aachen, Germany.

ORCID-Profile: Karina Sato-Espinoza, Robert A Vierkant, Perapa Chotiprasidhi, Filippo Pinto E Vairo, Shulan Tian, Jun Ma, Daniel O'Brien, Konstantinos N Lazaridis, Carola Dlugosch, Carolin Scheider, Alina M Allen, Kirk J Wangensteen

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS
  • national institutes of health national cancer institute
  • National Center for Advancing Translational Sciences

Zitieren

APA

Sato-Espinoza, K., Vierkant, R. A., Chotiprasidhi, P., Vairo, F. P. E., Tian, S., Ma, J., O'Brien, D., Lazaridis, K. N., Dlugosch, C., Scheider, C., Allen, A. M., & Wangensteen, K. J. (2025). Clinical and Genetic Predictors of Non‐Alcoholic Steatotic Liver Disease and Fibrosis in Lean Individuals. Liver International. https://doi.org/10.1111/liv.70300

Vancouver

Sato-Espinoza K, Vierkant RA, Chotiprasidhi P, Vairo FPE, Tian S, Ma J, et al. Clinical and Genetic Predictors of Non‐Alcoholic Steatotic Liver Disease and Fibrosis in Lean Individuals. Liver International. 2025. doi:10.1111/liv.70300

BibTeX
@article{SatoEspinoza2025,
  author = {Sato-Espinoza, Karina and Vierkant, Robert A and Chotiprasidhi, Perapa and Vairo, Filippo Pinto E and Tian, Shulan and Ma, Jun and O'Brien, Daniel and Lazaridis, Konstantinos N and Dlugosch, Carola and Scheider, Carolin and Allen, Alina M and Wangensteen, Kirk J},
  title = {Clinical and Genetic Predictors of Non‐Alcoholic Steatotic Liver Disease and Fibrosis in Lean Individuals},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70300}
}
Kostenlos starten →